BeOne’s new lung cancer drug: Response rate declines, while durability and brain penetration data support continued development
After the BGB-58067 sample was expanded, the objective response rate fell from 31.7% to 25.3%. However, newly disclosed data on duration of response, progression-free survival and intracranial efficacy led JPMorgan to continue supporting a pivotal lung cancer study in 2027.
J.P. Morgan ·